Skip to main content
Clinical Trials/NCT06690099
NCT06690099
Recruiting
Not Applicable

Prospective Collection of Whole Blood Specimens From RhD Negative Pregnant Women

Devyser Inc.1 site in 1 country500 target enrollmentApril 7, 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rhesus D Genotype
Sponsor
Devyser Inc.
Enrollment
500
Locations
1
Primary Endpoint
Fetal RhD determination from maternal whole blood
Status
Recruiting
Last Updated
11 months ago

Overview

Brief Summary

The purpose of this research is to collect blood samples and data from pregnant women who are Rh negative. The blood will be used for the future research and the development of non-invasive prenatal tests to identify Rh blood type status of the baby during pregnancy.

Detailed Description

This is a prospective multi-center blood collection study. Women 18 years of age or older with a viable singleton pregnancy between12 weeks and 28 weeks gestation will be enrolled. Whole blood samples will be collected from each enrolled patient. Maternal specimens will be processed to plasma and stored for future testing with non-invasive prenatal tests to identify fetal Rh status. Baby RhD blood type status will be recorded after delivery. All obstetric clinical management will take place per standard clinic practices and procedures and will not be altered by participation in the study.

Registry
clinicaltrials.gov
Start Date
April 7, 2025
End Date
December 2026
Last Updated
11 months ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Devyser Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Willing and able to provide written informed consent
  • 18 years of age or older at enrollment
  • Women with a viable pregnancy (with documented fetal heartbeat) between 12 weeks, 0 days and 28 weeks, 0 days gestational age
  • Women with RhD negative antigen status by serology
  • Willing to provide neonatal ABO and RhD genotyping status

Exclusion Criteria

  • Women with multiple gestation pregnancy

Outcomes

Primary Outcomes

Fetal RhD determination from maternal whole blood

Time Frame: 18 months

Collected samples will be used for future development of non-invasive prenatal test to determine fetal RhD status from maternal whole blood

Study Sites (1)

Loading locations...

Similar Trials